(Q53062915)

11 May 2018

title

Sipuleucel-T and immunotherapy in the treatment of prostate cancer. (English)

1 reference

11 May 2018

1 reference

Nancy A Dawson

1

1 reference

11 May 2018

Erin E Roesch

series ordinal

2

1 reference

11 May 2018

language of work or name

English

0 references

publication date

12 March 2014

1 reference

11 May 2018

Expert Opinion on Biological Therapy

published in

1 reference

11 May 2018

volume

14

1 reference

11 May 2018

issue

5

1 reference

11 May 2018

page(s)

709-719

1 reference

11 May 2018

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Characterising the castration-resistant prostate cancer population: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Regulation of adaptive immunity by the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

γδ T Cells Link Innate and Adaptive Immune Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Immunotherapy of cancer in 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Cancer immunotherapy comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Assessing oncologic benefit in clinical trials of immunotherapy agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Improved Endpoints for Cancer Immunotherapy Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Cancer vaccines: moving beyond current paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Activation of thymic regeneration in mice and humans following androgen blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Prostate cancer as a model for tumour immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Enhancing efficacy of therapeutic vaccinations by combination with other modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Impact of tumour volume on the potential efficacy of therapeutic vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Abiraterone in metastatic prostate cancer without previous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Listening to Provenge--what a costly cancer treatment says about future Medicare policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Pharmaco-economic aspects of sipuleucel-T.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Alpha emitter radium-223 and survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896897

10.1517/14712598.2014.896897

21 January 2018

Identifiers

DOI

1 reference

11 May 2018

release_c3itn5pi45g6vmmucu7chfb6ya

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/c3itn5pi45g6vmmucu7chfb6ya

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

11 May 2018